Ardent Health Inc.

Ardent Health Inc. (ARDT) Market Cap

Ardent Health Inc. has a market capitalization of $1.53B.

Price: $10.67

-0.06 (-0.56%)

Market Cap: 1.53B

NYSE · time unavailable

CEO: Dave Caspers

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2024-07-18

Website: https://www.ardenthealth.com

Ardent Health Inc. (ARDT) - Company Information

Market Cap: 1.53B|Sector: Healthcare

Company Profile

Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States. The company offers general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services within inpatient and ambulatory care settings. It also operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers, urgent care centers, free-standing emergency departments, and diagnostic imaging centers. The company operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. Ardent Health, Inc. was formerly known as Ardent Health Partners, Inc. and changed its name to Ardent Health, Inc. in June 2025. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health, Inc. is a subsidiary of EGI-AM Investments, L.L.C.

Analyst Sentiment

67%
Buy

From 12 Active Polls

1Y Forecast: $13.00

▲ +21.8% Potential Upside

Consensus Target Metrics

Low Bound

$13

Median

$13

High Bound

$13

Average

$13

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$13.00
▲ +21.84% Upside
Low Target
$13.00
22% Risk
Median Target
$13.00
22% Mid
High Target
$13.00
22% Max
Consensus
Buy
8 / 12 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)1,5301,2091,2431,8631,9151,9262,4382,5202,293
Enterprise Value ($M)3,2062,8852,7983,5293,6413,7074,1644,2094,207
Price to Earnings Ratio (P/E)11.237.646.90-19.496.5711.465.3424.1813.38
Price/Earnings-to-Growth Ratio (PEG)3.840.660.496.04
Price to Sales Ratio (P/S)0.240.750.771.181.161.291.521.741.56
Price to Book Ratio (P/B)0.870.700.741.501.531.642.162.513.10
Price to Free Cash Flow Ratio (P/FCF)7.15-13.699.0220.0326.87-40.3863.6751.7629.00
Enterprise Value to Sales (EV/Sales)1.801.742.242.212.482.592.902.86
Enterprise Value to EBITDA (EV/EBITDA)6.3422.4819.1963.4520.6929.7621.3038.8130.78
Debt to Equity Ratio3.311.321.341.841.811.942.022.243.04

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ARDENT HEALTH INC (ARDT) — Investment Overview

🧩 Business Model Overview

Ardent Health Inc operates a healthcare delivery platform centered on hospital and outpatient care across defined service areas. The value chain runs from (i) patient access and provider referral patterns, to (ii) care delivery through inpatient and outpatient clinical services, to (iii) reimbursement collection driven by payer contracts (commercial insurers, government payers) and a complex revenue cycle process. Revenue durability depends on maintaining sufficient patient volumes, care quality metrics that preserve reimbursement eligibility, and contracted rates under managed care arrangements.

Stickiness is reinforced by clinical continuity and operational network effects: patients tend to return to familiar sites of care for follow-up, diagnostic work, and procedures; physicians build referral behavior around available specialties, bed capacity, and service-line capabilities; and centralized administrative functions create practical switching costs for payers and referring providers once contracts and workflows are embedded.

💰 Revenue Streams & Monetisation Model

Revenue is primarily generated from healthcare services billed to payers under a mix of negotiated commercial rates and regulated government reimbursement frameworks. Monetisation is largely transactional (per episode/procedure), but with recurring characteristics driven by (i) ongoing payer contracting cycles, (ii) repeat utilization patterns in chronic and post-acute care pathways, and (iii) the operating leverage created when patient volumes stabilize.

Margin drivers typically include:

  • Payer mix and reimbursement rates (commercial vs. government; contractual rate coverage vs. cost structure).
  • Service-line mix (higher acuity/high complexity services often carry different reimbursement and cost profiles than lower-acuity outpatient activity).
  • Operating efficiency (length of stay management, staffing productivity, supply chain controls).
  • Revenue cycle performance (coding accuracy, denials management, timely claims resolution).

🧠 Competitive Advantages & Market Positioning

Ardent’s most defensible advantages are less about brand and more about structural market access and operational integration. The core “moat” is the difficulty for competitors to replicate patient referral behavior, contracted reimbursement positioning, and service-line capacity in the same locality without significant time and capital.

Key moats to consider:

  • Switching costs (patients and referring clinicians): Continuity of care, established referral pathways, and existing medical record workflows make switching care sites meaningfully inconvenient, particularly for multi-visit treatment pathways.
  • Network effects (referrals and service-line availability): A dense local referral ecosystem can generate a reinforcing loop—availability of specialties, imaging, emergency/acute capacity, and procedure throughput improves clinician confidence, which supports volume stability.
  • Regulatory and operational barriers: Licensure, accreditation, clinical staffing standards, payer credentialing, and CMS-related compliance requirements create sustained entry friction and raise the cost of competing.
  • Cost advantages via scale and procurement: While healthcare remains labor-intensive, larger contracting volume and centralized operations can reduce per-unit administrative cost and improve supply chain terms.
  • Integrated ecosystem: Coordinated inpatient-outpatient workflows can support case management, reduce avoidable utilization, and improve throughput.

Competitive benchmarking:

  • HCA Healthcare (HCA) — a large national operator with broader service-line depth and scale. Compared with Ardent, HCA often benefits from larger system-wide procurement leverage and diversified geographic exposure.
  • Tenet Healthcare (THC) — focused on community hospital operations and service-line expansion in major markets. Tenet’s national footprint can support bargaining power, though local competitors can still win through integrated physician relationships and site-specific capacity.
  • Universal Health Services (UHS) — differentiated by specialty and behavioral health exposure. UHS may access different demand pools than Ardent, while Ardent’s positioning is tied more closely to the general acute and outpatient needs of its service areas.

Positioning contrast: Ardent’s competitive center of gravity is typically the strength of its local delivery ecosystem—patient access, clinical breadth within its footprint, and contracted payer relationships—rather than purely system-wide scale.

🚀 Multi-Year Growth Drivers

  • Demand growth in healthcare utilization: Aging demographics and chronic disease prevalence support steady long-term healthcare volume needs, sustaining utilization for acute and outpatient services.
  • Site-of-care shift toward outpatient and specialty pathways: Healthcare systems invest in outpatient expansion and ambulatory service lines to capture more procedures and reduce avoidable inpatient admissions.
  • Value-based care and care management capabilities: Contracting structures that reward quality, cost discipline, and improved outcomes can expand earnings resilience when operational execution is strong.
  • Throughput and capacity optimization: Efficient staffing models, scheduling discipline, and process improvement can convert incremental demand into better operating leverage.
  • Revenue cycle and coding refinement: Ongoing tightening of claim submission, payer documentation, and denial reduction can sustain cash conversion and margin quality.

TAM expansion is less about a broad “new market” and more about capturing a larger share of local episodes—through service-line capabilities, payer contracting performance, and referral ecosystem strength—within an existing demand base that grows over time.

⚠ Risk Factors to Monitor

  • Reimbursement pressure and payer leverage: Government reimbursement rates, commercial rate resets, and denials pressure can compress margins without corresponding cost takeout.
  • Labor cost inflation and workforce constraints: Healthcare margins are sensitive to staffing availability and wage rates; sustained increases can outpace revenue growth.
  • Regulatory compliance and reimbursement rules: Changes to CMS policies, documentation requirements, readmission penalties, and quality reporting can affect allowable revenue and cost to comply.
  • Capital intensity: Facilities, clinical equipment, and health IT infrastructure require continuous investment to maintain competitiveness and meet compliance standards.
  • Technology and clinical execution risk: Clinical outcomes, coding accuracy, cybersecurity, and operational process maturity can influence both reimbursement and reputation.
  • Concentration and competitive dynamics: Regional competitors and payer contracting strategy can shift market share and case mix.

📊 Valuation & Market View

Healthcare provider valuation typically reflects operating margin durability and cash conversion rather than fast growth expectations. Market participants often anchor on:

  • EV/EBITDA or enterprise value to operating earnings (with attention to normalization for one-time items).
  • EV/Revenue when margins are in transition, particularly around service-line changes or contracting environments.
  • Free cash flow quality, including working capital dynamics tied to revenue cycle performance.

Drivers that move valuation include sustainable improvements in operating efficiency, evidence of stable or improving reimbursement capture, disciplined capital allocation, and credible progress on labor and revenue cycle performance amid reimbursement and policy uncertainty.

🔍 Investment Takeaway

Ardent Health Inc’s long-term investment case rests on structural market access in its service areas, supported by switching costs created by care continuity, network effects from referral ecosystems, and barriers stemming from regulatory and operational credentialing. The central question for multi-year compounding is execution: maintaining contracted reimbursement strength while improving efficiency, revenue cycle performance, and throughput—despite policy-driven reimbursement variability and labor intensity.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for ARDT.

zacks.com2026-07-28

Ardent Health, Inc. (ARDT) Expected to Beat Earnings Estimates: Should You Buy?

Ardent Health, Inc. (ARDT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

gurufocus.com2026-07-23

Kaskela Law Firm Announces Investigation of Ardent Health, Inc. (ARDT) and Encourages Long-Term ARDT Shareholders with Investment Losses to Contact the Firm

Investor litigation firm [url="]Kaskela Law[/url] announces that it is investigating Ardent Health, Inc. (NYSE: ARDT) (“Ardent”) on behalf of the company's

businesswire.com2026-07-23

Ardent Health surpasses 1 million patient encounters supported by ambient AI

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT) today announced that its physicians and advanced practice providers have surpassed 1 million patient encounters supported by Ambience Healthcare's ambient AI platform, marking a significant milestone in the organization's efforts to reduce clinician burnout, improve the provider experience and strengthen patient care. Ardent-affiliated clinicians using Ambience leverage the technology in 87% of ambulatory encounters across specialtie.

businesswire.com2026-07-23

Kaskela Law Firm Announces Investigation of Ardent Health, Inc. (ARDT) and Encourages Long-Term ARDT Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Ardent Health, Inc. (NYSE: ARDT) (“Ardent”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/ardent/ Recently a securities fraud complaint was filed against Ardent on behalf of certain investors who purchased shares of the company's stock between July 18, 2024 and November 12, 2025 (the “Wrongdoing Period”). According to the com.

businesswire.com2026-07-17

Ardent Health Announces Second Quarter 2026 Results Conference Call and Webcast Date

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its second quarter 2026 results after the market closes on Tuesday, August 4, 2026. A conference call will be held the following day, Wednesday, August 5, 2026, at 10 a.m. ET to review the Company's financial results and conduct a question-and-answer session. A webcast of the conference call and accompanying pr.

zacks.com2026-06-29

Do Options Traders Know Something About Ardent Health Stock We Don't?

Investors need to pay close attention to ARDT stock based on the movements in the options market lately.

fool.com2026-06-12

Is Ardent Health Stock a Buy After a Director Purchased More Than 11,000 Shares?

Robert DeMichiei acquired 11,260 shares on June 5, 2026, for a transaction value of approximately ~$98,000 at around $8.73 per share. This purchase increased DeMichiei's direct holdings by 46%, bringing his total direct ownership to 35,564 shares post-transaction.

seekingalpha.com2026-06-10

Ardent Health, Inc. (ARDT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Ardent Health, Inc. (ARDT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

businesswire.com2026-06-02

Ardent Health Appoints Dave Caspers as CEO

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT) (“Ardent Health” or the “Company”), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that Dave Caspers has been appointed President and Chief Executive Officer, effective immediately. Mr. Caspers, who previously served as Chief Operating Officer, succeeds Marty Bonick, who has stepped down to pursue other opportunities. In addition, Mr. Caspers has been appointed to the Company'.

businesswire.com2026-05-14

Ardent Health and Fujifilm Partner to Deliver Synapse Enterprise Imaging Across Radiology and Cardiology Throughout All Facilities

BRENTWOOD, Tenn. & LEXINGTON, Mass.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., has partnered with FUJIFILM Healthcare Americas Corporation to implement its Synapse® enterprise imaging solutions across Ardent's acute care hospital footprint across six states. Fujifilm's Synapse Enterprise Imaging solutions will provide Ardent clinicians with a single, holistic view of patient imaging data across various d.

seekingalpha.com2026-05-13

Ardent Health, Inc. (ARDT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Ardent Health, Inc. (ARDT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com2026-05-06

Ardent Health, Inc. (ARDT) Q1 2026 Earnings Call Transcript

Ardent Health, Inc. (ARDT) Q1 2026 Earnings Call Transcript

zacks.com2026-05-05

Ardent Health, Inc. (ARDT) Surpasses Q1 Earnings and Revenue Estimates

Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.29 per share a year ago.

businesswire.com2026-05-05

Ardent Health Reports First Quarter 2026 Results

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health, Inc. (NYSE: ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced results for the quarter ended March 31, 2026. First Quarter 2026 Operating and Financial Summary All comparisons are versus the same prior year period. See the footnotes to the Operating Statistics table of this press release for definitions of the metrics below and a full list of key oper.

businesswire.com2026-05-01

Ardent Health to Participate in the Bank of America 2026 Healthcare Conference

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that the Company will participate in the Bank of America 2026 Healthcare Conference on Wednesday, May 13, 2026, in Las Vegas, Nevada. Members of the management team will participate in a fireside chat on May 13, 2026, at 11:00 a.m. ET. A live audio webcast of the event will be available in the Investor Relations section of the Co.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"ARDT reported Q1’26 revenue of $1.60B and net income of $39.9M (EPS $0.28). On a YoY basis, revenue increased to $1.60B vs. $1.50B in Q1’25 (+7.0%), while net income rose to $39.9M vs. $41.4M (+-3.7%). On a QoQ basis, revenue was slightly down from Q4’25 ($1.61B; -0.2%), and net income declined from $44.96M (-11.3%). Profitability improved vs. Q1’25 with net margin at 2.49% vs. 2.76%, but operating performance was softer than Q4’25 (operating margin 4.66% vs. 6.53%). Cash flow quality weakened in the quarter: operating cash flow was -$60.2M and free cash flow was -$88.3M, reversing the strong cash generation in Q4’25 (OCF $221.8M; FCF $137.8M). Balance sheet resilience remains mixed—cash fell to $610M from $710M, while total assets were broadly stable around $5.25B; leverage is elevated with net debt still substantial (~$603M) and long-term debt roughly $1.18B. Total shareholder returns are currently challenged: the stock price is $9.91 with 1-year change of -19.43%, implying negative capital appreciation and no dividend support (dividend yield 0%)."

Revenue Growth

Positive

YoY revenue growth of +7.0% in Q1’26 ($1.60B vs. $1.50B in Q1’25). QoQ revenue was essentially flat/down slightly (-0.2% vs. Q4’25).

Profitability

Fair

Net income was down YoY by -3.7% and down QoQ by -11.3%. Net margin slipped to 2.49% from 2.76% YoY, and operating margin contracted vs. Q4’25 (4.66% vs. 6.53%).

Cash Flow Quality

Neutral

Operating cash flow turned negative (-$60.2M) and free cash flow was -$88.3M in Q1’26, a sharp deterioration from Q4’25 (OCF +$221.8M; FCF +$137.8M).

Leverage & Balance Sheet

Fair

Assets broadly stable (~$5.25B) but liquidity decreased (cash $610M vs. $710M QoQ). Leverage remains meaningful with net debt about $603M and long-term debt at ~$1.18B.

Shareholder Returns

Caution

No dividend (yield 0%). Price momentum is negative: 1y_change -19.43%, indicating capital depreciation rather than appreciation.

Analyst Sentiment & Valuation

Fair

Consensus target ~$13.33 vs. current ~$9.91 suggests upside, but without valuation/price momentum support from recent total returns.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

ARDT delivered strong Q1 2026 results despite weather and a lighter flu season, with adjusted EBITDA up 26% to $124M and +110 bps margin expansion to 7.7%. Cost execution was central: SWB improved +260 bps, contract labor fell >40% to $15M and dropped to 2.2% of SWB, and labor expense per AA declined 1.4% while supply efficiency added incremental benefit. Management reiterated the IMPACT program plan—$55M savings in 2026—and framed improvements as repeatable/structural rather than one-off. On demand, adjusted admissions grew 2.0% (midpoint of 2026 guidance 1.5%–2.5%) and surgeries rose 1.2%, led by outpatient +1.7%. Key headwinds remain payer denials and exchange dynamics: the $35M exchange EBITDA headwind is being managed with Ensemble, with silver-to-bronze mix worsening (~12%) and potential uninsured/claw-back exposure reserved. Outlook confidence is positive, but guidance was reaffirmed given the early-year timing and ongoing contracting/denial pressure risk.

AI IconGrowth Catalysts

  • Total surgeries +1.2% Y/Y; outpatient surgery +1.7% and outpatient/access-point strength supporting demand despite weather
  • Adjusted admissions +2.0% Y/Y (within 2026 guidance range of 1.5%–2.5% and described as at the midpoint)
  • IMPACT-driven throughput and labor/supply efficiency improvements supporting margin expansion even with seasonally weaker Q1 volume

Business Development

  • hellocare.ai partnership to deploy an enterprise-wide AI-assisted virtual care platform across 2,000+ patient rooms; deployment underway with expected completion by year-end
  • Ensemble named as revenue cycle partner to manage denial management, recovery efforts, and exposure for exchange disenrollments/claw-backs
  • Vendor model shift (single/dual-sourced) for physician preference items to improve rebates

AI IconFinancial Highlights

  • Revenue $1.6B (+7% Y/Y)
  • Adjusted EBITDA $124M (+26% Y/Y); adjusted EBITDA margin +110 bps to 7.7%
  • Pre-NCI adjusted EBITDAR margin +100 bps to 11.5%
  • Excluding $10.9M pre-tax other operating expense gain (investment option carrying value), adjusted EBITDA growth stated as +15%
  • SWB expense improved +260 bps as % of revenue (precision staffing and reduced reliance on contract labor)
  • Salaries, wages & benefits expense per AA reduced 1.4%; supply expense per AA growth +1.7%
  • Contract labor as % of SWB improved to 2.2% (from 3.8% in Q1 2025 and 2.6% in Q4 2025)
  • Contract labor expense reduced >40% to $15M in Q1
  • Supply expense as % of revenue improved +50 bps Y/Y (rebates and vendor leverage under IMPACT)
  • Professional fees +100 bps Y/Y as % of revenue; sequential +2.4% consistent with expectations tied to Q3 2025 step-up
  • Bad debt/collectibles and denials discussed as in line with embedded expectations; no material trajectory change cited
  • Exchange dynamic: admissions on exchanges +1% to +2%, but metal mix shifted silver to bronze (~12%), implying lower EBITDA throughput versus volume

AI IconCapital Funding

  • Total cash: $610M; total debt: $1.1B
  • Total available liquidity: $0.9B
  • Capital expenditures: $28M in Q1, expected to ramp through the year
  • Net leverage: 1.0x; lease adjusted net leverage: 2.6x (improved from 3.0x at end of Q1 2025)
  • No buyback or specific repurchase authorization/amount mentioned in transcript

AI IconStrategy & Ops

  • Capacity IQ system-wide capacity/demand and clinical talent deployment strategy referenced as supporting volume/mix/throughput
  • Precision staffing focus: speed to hire, scheduling, premium pay, overtime to limit contract labor dependence
  • IMPACT program: $55M savings target for 2026 reiterated; improvements characterized as repeatable/structural (staffing, supply chain, throughput)
  • Supply chain actions: improved rebates on physician preference items via single/dual-sourced vendor model; renegotiated cardiovascular and med-surg distribution contracts
  • Outpatient/ambulatory expansion: opened 4 urgent care centers in Texas, New Mexico, Idaho in Q1; for remainder of 2026, expects to open 2 ASCs, 1 freestanding ED, and 1 urgent care facility
  • AI/digital tools: virtual patient monitoring (including virtual sitting) already live; early use demonstrated ability to prevent harm

AI IconMarket Outlook

  • 2026 adjusted admissions guidance range referenced: 1.5% to 2.5%; Q1 at 2.0% described as midpoint
  • Full-year financial guidance reaffirmed; management stated Q1 is too early to adjust guidance post one quarter
  • Seasonality framing: historically strongest Q4 and weakest Q1; expecting Q2 and Q3 more comparable; modest step-up from Q1 to Q2 driven by IMPACT throughput (excluding $10.9M investment gain, basing step-up off an assumed ~113 number)
  • IMPACT savings: on track to deliver $55M in 2026

AI IconRisks & Headwinds

  • Severe winter storms affected Texas, Oklahoma, New Jersey; transient admissions disruption and labor/throughput rescheduling required
  • Lighter flu season cited as impacting admissions; winter/respiratory seasonality described as a recurring operational adjustment
  • Exchange headwinds: $35M EBITDA headwind referenced; risk of uninsured exposure/claw-backs for disenrollments after quarter end
  • Exchange metal mix deterioration: silver to bronze shift (~12%) increases patient copays/deductibles and reduces revenue/EBITDA throughput despite slightly higher exchange admissions
  • Payer denial trends: described as stabilizing but denials remain too high across the industry
  • Managed care contracting: some open negotiations for rate increases in 2026/into 2027; focus on denial/underpayment contract language
  • Professional fees comp: step-up begun in Q3 2025; year-over-year professional fee growth expected to moderate (management indicated single-digit/high-single-digit vs double-digit trajectory)
  • Medicaid: essentially flat overall, with redetermination activity cited; admissions slightly down in both Medicare and Medicaid attributed to mix/flu/respiratory effects (no guidance deviation stated)

Q&A: Analyst Interest

  • Topic: Q2/Q3 EBITDA progression vs Q1 and how one-time items affect run-rate: Management explained typical seasonality (Q4 strongest, Q1 weakest) and expected Q2 and Q3 to be comparable. They projected a modest Q1-to-Q2 step-up driven by IMPACT throughput, while excluding the $10.9M investment gain and basing the step-up on a ~113 figure. They also noted no significant supplemental approvals pending.
  • Topic: Contract labor reduction drivers and remaining runway: Management described “precision staffing” with reduced agency reliance: renegotiating a key agency contract to improve rates, systemically reallocating labor across the footprint, and focusing on speed-to-hire, scheduling, premium pay, and overtime. They cited contract labor as 2.2% of SWB in Q1 (down from 3.8% in Q1’25 and 2.6% in Q4’25) and stated they are stabilizing near pre-pandemic levels.
  • Topic: Exchange headwind mechanics, uninsured exposure, and metal mix impact on EBITDA: Management clarified Q1 performance matched the $35M exchange EBITDA headwind expectation. They stated work with Ensemble includes reserving for claw-back exposure related to disenrollments/non-payment after quarter end. They also highlighted silver-to-bronze movement of ~12%, implying higher patient copays/deductibles and lower financial throughput, offsetting slight admission growth.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the ARDT Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for ARDT.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (ARDT)

© 2026 Stock Market Info — Ardent Health Inc. (ARDT) Financial Profile